PFX — System, Microarray-Based, Genome-Wide, Postnatal Chromosomal Abnormality Detection Class II

FDA Device Classification

Classification Details

Product Code
PFX
Device Class
Class II
Regulation Number
866.5920
Submission Type
Review Panel
PA
Medical Specialty
Immunology
Implant
No

Definition

A microarray-based, genome-wide, postnatal chromosomal abnormality detection system is used to qualitatively detect constitutional gains and losses in chromosomal copy numbers across the human genome using microarray methods. It is intended as an aid in the postnatal diagnosis of developmental delay and/or intellectual disability (DD/ID), congenital anomalies, and dysmorphic features in conjunction with other clinical information currently used in postnatal diagnosis. It is not intended to be used for standalone diagnostic purposes, prenatal or pre-implantation testing or screening, population screening, or for the detection of, or screening for, acquired or somatic genetic aberrations.

Recent 510(k) Clearances

K-NumberApplicantDevice NameDate
K163367agilent technologiesGenetiSure Dx Postnatal AssayAugust 11, 2017
DEN130018affymetrixCYTOSCAN(R) DXJanuary 17, 2014